Compare Avient Corporation (AVNT) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Avient Corporation vs State Street SPDR S&P Biotech ETF — how do they compare? Avient Corporation trades at $45.2 (market cap $4.17B), while State Street SPDR S&P Biotech ETF trades at $159.35. The key difference: Avient Corporation pays a 2.42% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals.
| AVNT | XBI | |
|---|---|---|
Market Cap | $4.17B | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $45.69 | $164.28 |
52-Week Low | $27.48 | $86.92 |
Enterprise Value | $5.62B | — |
Dividend Yield | 2.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AVNT trades at $45.33, down 0.7% today, with a bullish technical signal from moving averages but overbought RSI levels. The company reported strong Q2 2026 earnings of $0.96 per share, beating estimates, and raised full-year guidance. Revenue growth of 5.8% to $917 million reflects robust demand and operational efficiency. Analysts maintain a buy consensus with a $49.00 price target, citing momentum and value metrics.
Outlook is positive due to consistent earnings beats and dividend payments, but risks include high valuation (P/E 24.55) and potential margin pressure from input costs. Investors should monitor Q3 2026 results against the $0.79 EPS estimate for sustained growth confirmation.
XBI, the SPDR S&P Biotech ETF, trades at $159.39, up 0.86% on the day, with a bullish technical signal driven by moving averages. The fund holds 155 biotech stocks, benefiting from strong sector momentum, including a 17% gain in June 2026 (ETF Trends, 2026-07-01). Recent news highlights institutional buying and positive drug trial outcomes fueling the rally.
Outlook: Biotech sector tailwinds from M&A, AI drug discovery, and clinical successes support further upside, but high volatility and policy risks persist. Investors gain diversified exposure to small- and mid-cap biotech innovation, though the 0.35% expense ratio and lack of dividend yield may deter income-focused buyers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Avient Corporation
Avient Corporation is a global leader in specialized and sustainable material solutions. Formed from the legacy of PolyOne and Clariant’s masterbatch business, it provides highly engineered polymer formulations, color systems, and advanced composites that enhance the performance and sustainability of products in industries like healthcare, defense, and consumer packaging.
Read more on AVNT →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
